Novevac Inks Cove 19 Vaccine Is on Its Way to Approval From the Fda

The us is about to approve a fourth covid vaccine that could be a silver bullet solution to the anti vax crisis. The company says it has resolved the manufacturing issues that had delayed their application, and is now expected, or now expects, approval from the fda in the coming weeks. In clinical trials first published in january 21, nova vax nova Vaxs vaccine was up to 90 % effective in preventing severe cove ninetin infections. But questions remained about the company's manufacturing capabilities that have delayed its ability to bring the vaccine to market.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app